Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ITNK Immunotherapy for MHC-I Deficient Cancers
NCT03882840Phase 2
Key facts
- Status
- Recruiting
- Start
- Jan 2019
- Primary completion
- Jan 2028
- Countries
- 1
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
- Modality
- Cell Therapies
- Drugs
- CAR-ITNK
- Conditions
- cancer
01
Overview
Phase 2, open-label trial of CAR-ITNK in cancer (2 arms), sponsored by Second Affiliated Hospital of Guangzhou Medical University. Primary endpoint: Safety and tolerance of the ITNK cell immunotherapy at 2 years. Started Jan 2019; status: recruiting.
02
Design
2 arms- Study design
- Non-randomizedOpen-label
ITNK cell therapy group
Patient-originated and induced T-to-natural killer (ITNK) cells.
CAR-ITNK cell therapy group
Patient-originated and induced T-to-natural killer (ITNK) cells with CAR-engineered.
03
Who it enrols
Patients with advanced cancer expressing low or no MHC-I, with adequate organ function and available autologous T cells.
04
Endpoints
Primary
Safety and tolerance of the ITNK cell immunotherapy
Secondary
Percent of Patients with best response as either complete remission or partial remission
Beyond the preview
Go deeper on NCT03882840.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03882840.